• About
  • Subscribe
  • Advertise
  • Contact
Tuesday, December 9, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Local

Fears new buying group could limit patient freedom

by Myles Hume
May 11, 2021
in Business, Local, News
Reading Time: 4 mins read
A A
Honeysuckle is a joint venture between nib health funds and US-based health services company Cigna Corporation.

Honeysuckle is a joint venture between nib health funds and US-based health services company Cigna Corporation.

Share on FacebookShare on Twitter

The creep of US-style managed care in Australia and reduced competition in the optical market are among major concerns raised with the competition watchdog as it considers the formation of a new buying group to collectively negotiate contracts with healthcare providers.

The Australian Society of Ophthalmologists (ASO) and Optometry Australia (OA) recently lodged submissions with the Australian Competition and Consumer Commission (ACCC), which will decide whether Honeysuckle Health can form and operate the buying group for 10 years.

Honeysuckle is an equal joint venture between nib health funds and US-based health services company Cigna Corporation. If approved, the Honeysuckle buying group could collectively negotiate and administer contracts with hospitals, medical specialists, GPs and allied health professionals.

This would be done on behalf of ‘participants’ that may include other private health insurers, international medical and travel insurance companies, and government and semi-government payers of healthcare services.

Honeysuckle anticipates smaller private health insurers that currently outsource their contracting services to two existing buying groups are most likely to join its group. Larger players Medibank, Bupa, HCF and HBF – who conduct their own negotiations – may be interested in purchasing bespoke aspects.

The ACCC has received around 30 submissions about the proposed buying group.

While supporters argue it could reduce out-of-pocket costs for consumers, health bodies are worried about the level of control insurers will have over clinical care pathways. The potential size of the group is also unclear, with concerns it could have disproportionate market power.

ASO vice-president Dr Peter Sumich said Australia’s healthcare model allowed “control of the who, where and when of our private medical care”.

Dr Peter Sumich.

“US-style managed care places the insurer in the position to determine a patient’s treatment pathway. We wish to see patients continue with full choice of care as decided in consultation with their doctor. Inevitably, insurers design care packages with a minimum viable product which may not be appropriate for all patients,” he said.

Sumich was part of an ASO delegation to Canberra where they raised concerns with Health Minister Greg Hunt’s office, as well as Opposition Health spokesperson Mr Mark Butler and Opposition Aged Care spokesperson Ms Ged Kearney.

“The discussions related to the creep of managed care under the trojan horse of Honeysuckle Health, Medibank vertical integration and HCF obstetric bundled care pathways,” Sumich said.

“Their response was one of concern and surprise because these individual commercial developments are not always put together to reveal the emerging patterns we all see as clinicians at the coalface.”

The ASO is also concerned Honeysuckle would compare the value of services from a provider against peers in the region.

“Many clinicians operate on different levels of complexity which sees some clinicians appear high quality, but only because they operate in a very limited range and on simple conditions,” its submission said. “In other cases, highly talented and reputed clinicians, who operate on most serious and complicated conditions, are marked down in this simplistic non-qualified system.”

Optical competition could be compromised 

OA’s submission stated larger funds and buying groups often entered low or ‘no gap’ contracting arrangements with the largest optometry providers only.

“Our concerns include that funds/buying groups that limit particular contracting arrangements to particular providers deny smaller optometry providers the opportunity to participate, compromising fair competition and can disadvantage policy holders in areas (typically rural) where such providers are not available,” the OA submission stated.

“We have concerns that a buying group, such as the proposed [Honeysuckle buying group], that includes at least one larger fund, and may potentially include multiple larger funds, by undertaking contracting arrangements for a potentially larger proportion of the health insurer market, will further compromise the capacity of smaller providers to compete fairly in the market, with the ultimate impact of reduced competition in the optometry/optical market.”

More reading

Optometrists concerned over health fund letters that left patients ‘confused’

Health fund data shows allied health is back to pre-pandemic levels

Health funds not hiding ‘pot of gold’

Tags: ACCCASOAustralian Competition and Consumer CommissionAustralian Society of OphthalmologistsCigna CorporationHoneysucklenib health fundsOAOptometry Australia

Related Posts

Actress and entrepreneur Naomi Watts is promoting eye health as part of healthy ageing. Image: Denis Makarenko/shutterstock.com.

Aussie star Watts, J&J team up to promote eye health

by Staff Writer
December 9, 2025

Johnson & Johnson, a global leader in eye health, has partnered with Australian Academy Award–nominated actress, producer, and entrepreneur Ms...

Mr Mark Nevin began his professional life as an
optometrist in Ireland and the UK. Image: Optometry Australia

Optometry Australia announces new CEO

by Staff Writer
December 9, 2025

Optometry Australia (OA) has appointed Mr Mark Nevin as CEO, following the departure of Ms Skye Cappuccio, who was at...

Holly Cafe worked her way through nearly every role on the retail side during her journey to partnership. Image: Holly Cafe.

Owning the vision – pathways to partnership

by Rhiannon Bowman and Rob Mitchell
December 8, 2025

Three dispensing and retail directors tell Insight how they made their way to investing in an optometry practice – sometimes...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited